Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

£2.6m for radical new treatment for kidney dialysis patients

15.02.2006


An innovative new medical approach which could substantially improve the quality of life for over a million kidney dialysis patients, and bring huge savings to health services around the globe has received an investment round worth £2.6m.



The development of this new product has been made possible thanks to a major funding round of £2.6m led by NPI Ventures with funding from NESTA (the National Endowment for Science, Technology and the Arts), who had previously invested £95,000 in the technology, Imperial College and Oxford Capital Partners.

At present, over a million kidney dialysis patients worldwide are treated by having a synthetic tube – called a vascular access graft - inserted under the skin, through which they are "hooked up" to a machine every few days.


Vascular access grafts are inserted beneath the skin so needles can be injected regularly and to maximise blood-flow to the dialysis machine. However, these can develop a potentially lethal disease, called ‘intimal hyperplasia’. This thickens the blood vessels, which is the most common reason for grafts needing to be replaced within a year, or for patients to undergo remedial surgery.

London-based Veryan Medical Ltd has developed SwirlGraft to combat this. It updates the standard synthetic grafts with a new spiral shape, allowing the blood to swirl through it, mimicking its natural action and reducing the likelikood of any problems.

By ensuring appropriate swirling blood flow through the dialysis graft and into the downstream vein, it stands to greatly reduce the disease by eliminating the stagnant flow regions where ‘intimal hyperplasia’ proliferates.

The SwirlGraft vascular access graft has undergone clinical trials at six hospitals in the Netherlands. During 2005 SwirlGraft was granted regulatory approvals in the US and Europe. This funding round will be used to develop the SwirlGraft and in particular to finance further clinical trials for the US market. The investment includes an option for a further £5.2m investment to further develop Veryan’s next high value product, the SwirlFlow vascular stent.

Mark White , Director of Invention & Innovation at NESTA, said:

"Veryan Medical is a great example of the kind of UK innovation our early stage seed funding is designed to support. Through investing in its innovative technology early on we are looking to ensure that this idea has every opportunity of being fully commercialised, benefiting patients, those working in healthcare, and the UK economy."

Joseph Meaney | alfa
Further information:
http://www.nesta.org.uk

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>